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OBJECTIVES The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of
sotalol in the treatment of fetal tachycardia.
BACKGROUND Maternally administered, intrauterine therapy of fetal tachycardia is dependent on the
transplacental passage of the antiarrhythmic agent.
METHODS In a prospective study of patients treated for fetal tachycardia with sotalol, concentrations of
sotalol were determined in maternal and umbilical blood and in amniotic fluid, and the
relationship between these concentrations and the occurrence of conversion to sinus rhythm
was investigated.
RESULTS Eighteen fetal patients were studied, nine with atrial flutter and nine with supraventricular
tachycardia. Fourteen were treated with sotalol; 13 converted to sinus rhythm, of whom 2
relapsed. There was one intrauterine death. Four patients were treated with sotalol and
digoxin, of whom two were treated successfully. Mean birth weight was 3,266 g. The daily
maternal sotalol dose was linearly related to the maternal plasma concentration. The mean
fetal/maternal sotalol plasma concentration was 1.1 (range 0.67 to 2.87, SD 0.63), and the
mean amniotic fluid/fetal blood ratio of sotalol was 3.2 (range 1.28 to 5.8, SD 1.4). The
effectiveness of sotalol therapy could not be extrapolated from maternal blood levels.
CONCLUSIONS Sotalol is a potent antiarrhythmic agent in the treatment of fetal tachycardia. The placental
transfer is excellent. Sotalol accumulates in amniotic fluid but not in the fetus itself. Therefore
it seems that renal excretion in the fetus is efficient and greater than the oral absorption by
fetal swallowing. The maternal blood level is not a reliable predictor of the chances of success
of therapy. Sotalol is not associated with fetal growth restriction. (J Am Coll Cardiol 2003;
42:765–70) © 2003 by the American College of Cardiology Foundation
Fetal tachycardia, defined as a heart rate greater than 180
beats/min, is a condition that occurs in approximately 0.4%
to 0.6% of all pregnancies (1). The subset of these cases with
more sustained periods of tachycardia and higher heart rates
is associated with congestive heart failure, fetal hydrops,
neurologic morbidity, and intrauterine death (2–5). Most
centers have therefore opted for prenatal intervention in the
form of maternal pharmacologic treatment (6–18). Its
success, however, depends largely on the amount of drug
that crosses the placenta, which is subject to the altered
maternal pharmacokinetics and pharmacodynamics in preg-
nancy. Various physiologic changes during pregnancy influ-
ence maternal pharmacokinetics. In addition, the fetal
plasma concentration is also influenced by changes in the
fetus itself. Studies on the maternal-placental-fetal unit are
limited for obvious ethical reasons; however, the treatment
of fetal tachycardia provides us with a unique opportunity to
investigate this matter. In the literature, data on the trans-
placental passage of sotalol are confined to two small studies
and one case report (19–21).
We present a study in which we have prospectively
investigated drug levels of sotalol in maternal blood, umbil-
ical cord blood after delivery and amniotic fluid. A correla-
tion between the success or failure of treatment of maternal-
fetal pharmacotherapy and blood concentrations in both
mother and neonate is presented.
METHODS
Definitions. Fetal tachycardia, defined as a sustained fetal
heart rate 180 beats/min, was diagnosed by M-mode
echocardiography and subdivided in supraventricular tachy-
cardia (SVT; 1:1 atrioventricular conduction) and atrial
flutter (AF; atrial rate 250 beats/min with a fixed or
variable atrioventricular block).
Congestive heart failure was diagnosed if fluid accumu-
lation existed in the fetal body, such as pericardial effusion,
pleural effusion, ascites, or skin edema. Fetal hydrops was
diagnosed if fluid accumulation existed in two or more of
these compartments.
Patients. All mothers who were diagnosed with fetal
tachycardia at the department of Obstetrics, University
Medical Center, Utrecht, from 1999 until 2002 were given
a detailed description of the study protocol and consented to
enter this study. A maternal history was obtained to exclude
preexisting arrhythmias, and a maternal electrocardiogram
(ECG) was made to exclude prolonged QT intervals.
Sotalol therapy was initiated at either 80 mg twice daily or
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160 mg twice daily, increased to a maximum of 160 mg
thrice daily, and the addition of digoxin in the event of
conversion to sinus rhythm did not occur (18,22). Patients
were regularly scheduled (at least once a week) for control
visits to evaluate the fetal heart rhythm and possible signs of
congestive heart failure. All deliveries took place at our
institution, and neonates were admitted immediately after
birth for at least 48 h for observation. Postnatal ECGs were
performed in all neonates.
Blood sampling. At every prenatal visit, a 5-ml blood
sample was drawn from a maternal peripheral vein to
measure maternal drug levels. At the time of delivery, 5 ml
of maternal blood, 5 ml of blood from the umbilical artery
and from the umbilical vein, and whenever possible 10 ml of
amniotic fluid was collected.
Drug analysis. Sotalol concentrations in plasma and am-
niotic fluid were determined by a modified ion-pair,
reversed-phase, high-performance liquid chromatography
method, with ultraviolet detection at 226 nm described by
Ka¨rkka¨inen (23). The lower limit of quantification was 0.08
mg/l with an intra-day coefficient of variation (CV) of 4.4%
at 0.02 mg/l and an inter-day CV of 2.6% at 0.02 mg/l (24).
Approval. The study was approved by the Medical Ethics
Review Committee of the University Medical Center Utre-
cht according to the Helsinki protocols.
RESULTS
Eighteen women agreed to participate in this study. Details
on diagnosis, treatment modalities, and outcome are sum-
marized in Figure 1. Of nine patients with AF, one fetus
was hydropic; two of nine fetuses with a SVT had conges-
tive heart failure. Fourteen patients received sotalol as single
therapy. Of these 14 patients, 10 converted to sustained
sinus rhythm in a mean time to conversion of 46 h (SD
32 h). In one additional patient, two weeks were required to
reach sustained sinus rhythm. Two patients, who initially
converted to sinus rhythm within 48 h, relapsed into
tachycardia after one and five weeks of sinus rhythm,
respectively. Because both patients had reached a gestational
age of 37 weeks at that time, a Caesarean section (SC) was
performed, rather than increasing the dosage or addition of
another antiarrhythmic agent. One nonhydropic fetus with
SVT died unexpectedly three days after initiation of therapy
with sotalol 160 mg twice daily. Sinus rhythm had not been
achieved. The maternal blood level of sotalol was 1.01 mg/l,
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Abbreviations and Acronyms
AF  atrial flutter
CV  coefficient of variation
ECG  electrocardiogram
F/M ratio  fetal/maternal sotalol plasma concentration
SC  Caesarean section
SVT  supraventricular tachycardia
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which is within the normal range. Autopsy showed signif-
icant dilation of the heart and minimal signs of hydrops. No
structural abnormalities were present.
In four patients, digoxin was added to the sotalol treat-
ment according to protocol because of persistent fetal
tachycardia. In two patients this was successful 24 h and
48 h after the addition of digoxin, respectively. One patient
was delivered by SC at 35 weeks and six days, after
membranes had ruptured spontaneously, and a prolapsed
arm was diagnosed; sinus rhythm had not been achieved
despite longstanding multiple drug therapy. The other
patient was delivered by SC at 36 weeks and six days
because of persistence of tachycardia despite six days of
multiple drug treatment.
Sotalol and digoxin levels. Maternal sotalol levels mea-
sured at the prenatal visits in all patients increased linearly
with increasing dose (Fig. 2). Umbilical vein samples were
obtained in 12 cases. The relationship between maternal
sotalol dosage and umbilical vein concentration is shown
in Figure 3. Maternal and fetal blood levels were almost
equal, and the mean fetal/maternal sotalol plasma concen-
tration (F/M ratio) was 1.11 (range 0.67 to 2.87, SD 0.63)
(Table 1).
Sotalol was measured in amniotic fluid in seven cases.
The concentration was higher in amniotic fluid than in fetal
cord blood and maternal blood, and the concentration ratios
were 3.2 (range 1.28 to 5.8, SD 1.4) and 2.94 (range 1.0 to
6.0, SD 1.6), respectively.
Correlation between maternal blood levels and success of
therapy. There did not seem to be a correlation between
sotalol blood concentrations and the occurrence of conver-
sion to sinus rhythm. The levels at which the drug proved to
be effective were only slightly higher than those that did not
result in conversion, indicating a large difference in sensi-
tivity to the drug. In three individual patients in which
sotalol initially was not effective, an increase in dose from 80
mg twice daily in two patients (blood levels 0.60 and 0.87
mg/l) to 160 mg twice daily (blood levels 1.27 and 1.63
mg/l) and from 160 mg twice daily in one patient (blood
level of 0.77 mg/l) to 160 mg thrice daily (blood level of
1.50) was associated with conversion to sinus rhythm,
whereas in one case a decrease in dose (from 160 mg twice
daily to 80 mg thrice daily) and serum level (1.75 mg/l to 0.6
mg/l) was associated with a relapse of AF.
Postnatal outcome. One fetus died in utero, and one
infant with a massive hydrops, delivered at 33 weeks and
four days, died two days after delivery. Follow-up is avail-
able for the other 16 infants, varying from 6 months to 36
months after birth. Eight infants (5 had AF and 3 had SVT)
had no rhythm disturbances during the newborn period, and
no medication was initiated. None of these patients have
developed episodes of tachycardia, and they are currently
doing well. Three patients showed AF at birth (two
therapy-resistant cases and one relapse), and all required
electrical cardioversion to reach sustained sinus rhythm.
These three patients are currently doing well and require no
Figure 2. Mean interquartile range and overall range of maternal blood levels of sotalol per daily dosage. Number of women with observations is shown
within brackets. A linear relationship between blood level and increasing dosage is shown.
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medication. Five patients showed SVT postnatally, of
whom two had Wolff-Parkinson-White syndrome, two had
persistent junctional reciprocating tachycardia, and one
patient showed intermittent periods of SVT of unknown
origin. All are doing well on antiarrhythmic therapy, con-
sisting of digoxin in two patients, propranolol in one
patient, and a combination of these two agents in two
patients. All surviving infants are in good neurologic
condition.
Postnatal corrected QT interval (QTc). The mean QTc
at the first day of life was 0.41 (range 0.35 to 0.47, SD
0.035), and no relationship with the maternal sotalol dosage
or fetal blood level was present.
Birth weight. The mean birth weight was 3,266 g (range
960 to 4,280 g, SD 804). All infants were appropriate for
dates with one exception. This baby was born at 33  4
weeks of gestational age with a birth weight of 960 g, which
is below 2.3rd percentile of normal birth weights for this
gestational age (25); this infant was only treated for four
days, and the low birth weight could therefore not be
attributed to the beta-blocking therapy.
DISCUSSION
Choice of drugs. The choice of sotalol as drug of first
choice was based on our previous experience with this drug.
As reported in a previous article, sotalol seems to be more
efficacious than other drugs in fetal AF (17). In fetal SVT,
conversion rates were comparable to that of other studies,
but a relatively high mortality rate was present, and we
called into question the use of sotalol in fetal SVT. How-
ever, after consideration of the data, no statistical difference
in mortality was present compared with that of other
studies, and therefore, the protocol in nonhydropic SVT
remained the same. In fetal SVT complicated by hydrops,
we opted for a different strategy as discussed in a previous
article (18), consisting of either flecainide orally or digoxin
intravenously, as these strategies seemed to be more
successful.
Success of therapy. In the patients treated with sotalol as a
single agent, results were favorable, because 13 of 14
patients converted to sinus rhythm in a relatively short
amount of time. Unfortunately, the one patient who went
into premature labor did not benefit long enough from sinus
Figure 3. Mean interquartile range and overall range of umbilical blood level of sotalol per daily maternal dosage. Number of observations is shown within
brackets.
Table 1. The Fetal/Maternal Ratios of Sotalol
Case No. F/M Sotalol
Amniotic Fluid/
Fetal Blood Ratio
1 0.83
2 0.75
3 0.75 4.0
4 1.79 3.15
5 1.02
6 1.14 2.57
7 0.85 3.11
8 0.67 2.49
9 0.72 5.8
10 2.87 1.28
11 0.82
12 1.1
Mean 1.11 3.2
SD 0.63 1.4
F/M sotalol  fetal/maternal sotalol plasma concentration.
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rhythm, as this only lasted for three days and hydrops was
still present at the time of delivery. The other two patients
who went into relapse clearly profited from in utero therapy
as they reached gestational maturity while on therapy. Our
choice of delivery by SC at that time, rather than the
increase of dosage or the addition of a second antiarrhyth-
mic agent, was based on our opinion that the possible
harmful effects of transplacental therapy (adverse effects of
mother, and potential proarrhythmic effects for both mother
and fetus) outweigh the benefits of further in utero matu-
ration. In the patient who was treated with both sotalol and
digoxin in which no conversion was reached at 36  6
weeks, the decision to perform a SC was based on the same
opinion. The conversion rates of 72% with sotalol, reaching
83% after the addition of digoxin, compare favorably with
the results of other treatment protocols using digoxin as the
drug of first choice, in which conversion rates of 50% to 71%
are reported (8,10–12).
The unexpected intrauterine death, possibly as a result of
ventricular fibrillation, raises the possibility of proarrhyth-
mic effects of sotalol in the fetus. Although we have no
evidence that this was indeed the cause of death, we think
that the possible risk of proarrhythmia should be mini-
mized. Intrauterine therapy should therefore always be
weighed against possible adverse effects. As proarrhythmia
of sotalol is known to be dose-related (26), low initiation
doses are preferable and dosage increases should be step-
wise. Close monitoring, especially during the initiation
phase, is recommended. In addition, maternal potassium
levels and magnesium levels should be monitored regularly
and supplemented if necessary.
We therefore propose a new dosage scheme with an
initiation dose of 80 mg of sotalol twice daily, stepwise
increased with 80 mg per three days to a maximum of
160 mg thrice daily. Digoxin may be added as a second-line
drug. This protocol has our preference in the treatment of
fetal AF, either with or without hydrops. We have no
definite preference for either sotalol or digoxin in the
treatment of nonhydropic fetal SVT. In fetal SVT compli-
cated by hydrops, other strategies seem to be more success-
ful.
Dosage and maternal blood levels. Despite high oral
sotalol dosages, all maternal blood levels remained below the
“toxic” level of 2.5 mg/l (at which marked QTc prolonga-
tion is noted). This is probably the result of the increased
blood volume and renal clearance in pregnant women. This
is important, as maternal adverse effects and the risk of
torsade de pointes tachycardia (as a result of QTc prolon-
gation) are dose-related. The F/M ratio of 1.11 shows that
the fetus also stays below the “toxic” level.
Fetal/maternal ratio of plasma concentration. Sotalol
passes the placenta easily and completely, as can be con-
cluded from the mean F/M ratio of 1.11. This result is
similar to that reported by O’Hare et al. (19), though it
differs from the lower ratio found in the study of Erkkola et
al. (20), although this could be explained by the nature of
the study in which only a single dose was administered 3 h
before delivery. The ratio of 1.11 compares favorably with
the F/M ratios of other commonly used drugs in fetal
tachycardia. Apparently sotalol does not accumulate in the
fetus, which implies that the excretion of sotalol by the fetal
kidney is efficient close to term. The adequate renal excre-
tion may explain the relatively high concentration of sotalol
in amniotic fluid. The high amniotic fluid/umbilical venous
blood ratio combined with an almost 1:1 relationship of
fetal and maternal blood and the swallowing of amniotic
fluid by the fetus implies that the elimination rate of sotalol
is greater than the oral reabsorption.
Correlation of maternal blood level and success of therapy.
Although in individual cases the maternal dosage of sotalol
was related to the success of therapy, statistically a strong
relationship between the maternal blood level and the
success of therapy was not shown. The therapy-resistant
cases required either electrical cardioversion or multiple
drug therapy, which suggests that the success of therapy may
be more related to the type of arrhythmia.
The maternal blood levels do, however, strongly relate to
the fetal blood level and could thus be valuable in preventing
exposure of the fetus to toxic levels.
Postnatal QTc. The QTc interval at the first day of life is
of potential interest, as repolarization may still be under the
influence of the class III antiarrhythmic properties of
sotalol. The effects of sotalol on the neonatal QTc interval
may be extrapolated to the fetal situation, although mea-
surement of the fetal QT interval by fetal magnetocardio-
graphy in future studies may be more reliable. The mean
QTc in our patients is somewhat higher than reported in
previous studies (27,28); however, it remains below 0.44, at
which point a lengthened QTc is diagnosed. The effects of
sotalol on repolarization in the dosages used in this study are
therefore, in our opinion, limited and do not reach “toxic”
limits.
Birth weight. Some beta-blockers, such as propranolol,
have been associated with intrauterine growth retardation
(29). All but one of our patients had birth weights within
the normal range, even though in several cases this treat-
ment was continued throughout the whole third trimester.
Therefore, it seems unlikely that sotalol induces fetal growth
restriction.
CONCLUSIONS
We conclude that sotalol is a potent antiarrhythmic agent in
the treatment of fetal tachycardia, especially in fetal AF
(with or without hydrops). Sotalol passes the placenta
quickly and reaches a steady-state level almost identical to
the maternal plasma level. Maternal blood levels can there-
fore be used as an indicator of the fetal blood levels. Sotalol
accumulates in amniotic fluid but not in the fetus itself,
indicating that renal excretion is efficient, and implying that
the elimination rate of sotalol exceeds oral absorption in
term fetuses. Maternal blood levels are not a reliable
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predictor of the chances of success of therapy. Sotalol is not
associated with fetal growth restriction.
Reprint requests and correspondence: Dr. Martijn A. Oudijk,
Department of Obstetrics, University Medical Center (UMC),
KE 04.123.1/P.O. Box 85090, 3508 AB, Utrecht, The Nether-
lands. E-mail: m.oudijk@azu.nl.
REFERENCES
1. Bergmans MGM, Jonker GJ, Kock HCL. Fetal supraventricular
tachycardia: review of the literature. Obstet Gynecol Surv 1985;40:
61–8.
2. Naheed ZJ, Strasburger JF, Deal BJ, Benson DW, Gidding SS. Fetal
tachycardia: mechanisms and predictors of hydrops fetalis. J Am Coll
Cardiol 1996;27:1736–40.
3. Schade RP, Stoutenbeek P, de Vries LS, et al. Neurological morbidity
after fetal supraventricular tachyarrhythmia. Ultrasound Obstet Gy-
necol 1999;13:43–7.
4. Sonesson SE, Winberg P, Lidegran M, Westgren M. Foetal supraven-
tricular tachycardia and cerebral complications. Acta Paediatr 1996;
85:1249–52.
5. Donn SM, Bowerman RA. Association of paroxysmal supraventricular
tachycardia and periventricular leukomalacia. Am J Perinatol 1993;10:
212–4.
6. Allan LD, Chita SK, Sharland GK, et al. Flecainide in the treatment
of fetal tachycardias. Br Heart J 1991;65:46–8.
7. Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal
supraventricular tachyarrhythmias. J Clin Ultrasound 1985;13:265–73.
8. Simpson JM, Sharland GK. Fetal tachycardias: management and
outcome of 127 consecutive cases. Heart 1998;79:576–81.
9. Cuneo BF, Strasburger JF. Management strategy for fetal tachycardia.
Obstet Gynecol 2000;96:575–81.
10. Van Engelen AD, Weijtens O, Brenner JI, et al. Management,
outcome and follow-up of fetal tachycardia. J Am Coll Cardiol
1994;24:1371–5.
11. Frohn-Mulder IM, Stewart PA, Witsenburg M, et al. The efficacy of
flecainide versus digoxin in the management of fetal supraventricular
tachycardia. Pren Diagn 1995;15:1297–302.
12. Jaeggi E, Fouron JC, Drblik SP. Fetal atrial flutter: diagnosis, clinical
features, treatment, and outcome. J Pediatr 1998;132:335–9.
13. Sonesson SE, Fouron JC, Wesslen-Eriksson E, et al. Foetal supraven-
tricular tachycardia treated with sotalol. Acta Paediatr 1998;87:584–7.
14. Ebenroth ES, Cordes TM, Darragh RK. Second-line treatment of
fetal supraventricular tachycardia using flecainide acetate. Pediatr
Cardiol 2001;22:483–7.
15. Krapp M, Baschat AA, Gembruch U, Geipel A, Germer U. Flecainide
in the intrauterine treatment of fetal supraventricular tachycardia.
Ultrasound Obstet Gynecol 2002;19:158–64.
16. Strasburger JF. Fetal arrhythmias. Prog Pediatr Cardiol 2000;11:1–17.
17. Oudijk MA, Michon MM, Kleinman CS, et al. Sotalol in the
treatment of fetal dysrhythmias. Circulation 2000;101:2721–6.
18. Oudijk MA, Ruskamp JM, Ambachtsheer BE, et al. Drug treatment
of fetal tachycardias. Pediatr Drugs 2002;4:49–63.
19. O’Hare MF, Murnaghan GA, Russell CJ, et al. Sotalol as a hypoten-
sive agent in pregnancy. Br J Obstet Gynaecol 1980;87:814–20.
20. Erkkola R, Lammintausta R, Liukko P, Antilla M. Transfer of
propranolol and sotalol across the human placenta: their effect on
maternal and fetal plasma renin activity. Acta Obstet Gynecol Scand
1982;61:31–4.
21. Darwiche A, Vanlieferinghen P, Lemery D, et al. Amiodarone and
fetal supraventricular tachycardia: apropos of a case with neonatal
hypothyroidism. Arch Fr Pediatr 1992;49:729–31.
22. Oudijk MA, Ambachtsheer EB, Stoutenbeek P, Meijboom EJ. Pro-
tocollen voor de behandeling van supraventriculaire tachycardiee¨n bij
de foetus. Ned Tijdschr Geneeskd 2001;145:1218–9.
23. Ka¨rka¨inen S. High-performance liquid chromatographic determina-
tion of sotalol in biological fluids. J Chromatogr 1984;336:313–9.
24. IJmker J, Bouma P, Uges DRA. Bepaling van sotalol. Ziekenhuis-
farmacie 1991;7:32.
25. Kloosterman GJ. Intrauterine growth and intrauterine growth curves.
Ned Tijdschr Verloskd Gynaecol 1969;69:349–65.
26. Hohnloser SH, Woosley RL. Drug therapy: sotalol. N Engl J Med
1994;331:31–8.
27. Schwartz PJ, Montemerlo M, Facchini M, et al. The QT interval
throughout the first six months of life: a prospective study. Circulation
1982;66:496–501.
28. Montague TJ, Taylor PG, Stockton R, et al. The spectrum of cardiac
rate and rhythm in normal newborns. Pediatr Cardiol 1982;2:33–8.
29. Pruyn SC, Phelan JP, Buchanon GC. Long term propranolol therapy
in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol
1979;135:485–9.
770 Oudijk et al. JACC Vol. 42, No. 4, 2003
Treatment of Fetal Tachycardia with Sotalol August 20, 2003:765–70
